Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study
| Autor: | Kondili, Loreta A., GAETA, Giovanni Battista, Ieluzzi, Donatella, Zignego, Anna Linda, Monti, Monica, Gori, Andrea, Soria, Alessandro, Raimondo, Giovanni, Filomia, Roberto, Leo, Alfredo Di, Iannone, Andrea, Massari, Marco, Corsini, Romina, Gulminetti, Roberto, Comini, Alberto Gatti, Toniutto, Pierluigi, Dissegna, Denis, Russo, Francesco Paolo, Zanetto, Alberto, Rumi, Maria Grazia, Brancaccio, Giuseppina, Danieli, Elena, Brunetto, Maurizia Rossana, Weimer, Liliana Elena, Quaranta, Maria Giovanna, Vella, Stefano, Puoti, Massimo, PITER Cohort Study, FEDERICO, Alessandro, Dallio, M, LOGUERCIO, Carmelina |
|---|---|
| Přispěvatelé: | Kondili, L, Gaeta, G, Ieluzzi, D, Zignego, A, Monti, M, Gori, A, Soria, A, Raimondo, G, Filomia, R, Leo, A, Iannone, A, Massari, M, Corsini, R, Gulminetti, R, Comini, A, Toniutto, P, Dissegna, D, Russo, F, Zanetto, A, Rumi, M, Brancaccio, G, Danieli, E, Brunetto, M, Weimer, L, Quaranta, M, Vella, S, Puoti, M, Kondili, Loreta A., Gaeta, Giovanni Battista, Ieluzzi, Donatella, Zignego, Anna Linda, Monti, Monica, Gori, Andrea, Soria, Alessandro, Raimondo, Giovanni, Filomia, Roberto, Leo, Alfredo Di, Iannone, Andrea, Massari, Marco, Corsini, Romina, Gulminetti, Roberto, Comini, Alberto Gatti, Toniutto, Pierluigi, Dissegna, Deni, Russo, Francesco Paolo, Zanetto, Alberto, Rumi, Maria Grazia, Brancaccio, Giuseppina, Danieli, Elena, Brunetto, Maurizia Rossana, Weimer, Liliana Elena, Quaranta, Maria Giovanna, Vella, Stefano, Puoti, Massimo, PITER Cohort, Study, Federico, Alessandro, Dallio, M, Loguercio, Carmelina |
| Rok vydání: | 2018 |
| Předmět: |
Genetics and Molecular Biology (all)
Male Cirrhosis Disease Hepacivirus Toxicology Biochemistry Viral infection 0302 clinical medicine 80 and over Medicine Prospective Studies Chronic lcsh:Science media_common Aged 80 and over Liver Diseases Drug Interaction Italy Adult Aged Antiviral Agents Drug Administration Schedule Drug Therapy Combination Female Hepatitis C Chronic Humans Interferons Liver Cirrhosis Middle Aged Risk Drug Interactions Medicine (all) Biochemistry Genetics and Molecular Biology (all) Agricultural and Biological Sciences (all) 030220 oncology & carcinogenesis Interferon 030211 gastroenterology & hepatology Human Cohort study Drug medicine.medical_specialty media_common.quotation_subject Drug-Drug Interactions Gastroenterology and Hepatology Microbiology 03 medical and health sciences Drug Therapy Pharmacology Hepaciviru Flaviviruses lcsh:R Organisms Correction medicine.disease Prospective Studie Regimen Immunology lcsh:Q RNA viruses lcsh:Medicine 030204 cardiovascular system & hematology medicine.disease_cause Cohort Studies Liver disease Drug Metabolism Medicine and Health Sciences 030212 general & internal medicine Prospective cohort study Pathology and laboratory medicine Multidisciplinary HCV DAA Hepatitis C virus Antiviral therapy Medical microbiology Hepatitis C Real life data Research Design Combination Viruses Pathogens Research Article Liver Cirrhosi Biology Research and Analysis Methods Chronic hepatitis Internal medicine Pharmacokinetics In patient Antiviral Agent Biology and life sciences Toxicity business.industry Interferon free Viral pathogens Hepatitis viruses Microbial pathogens business |
| Zdroj: | PLoS ONE, Vol 12, Iss 2, p e0172159 (2017) PLoS ONE PLoS ONE, Vol 13, Iss 1, p e0190803 (2018) |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0190803 |
| Popis: | Background There are few real-life data on the potential drug-drug interactions (DDIs) between anti-HCV direct-acting antivirals (DAAs) and the comedications used. Aim To assess the potential DDIs of DAAs in HCV-infected outpatients, according to the severity of liver disease and comedication used in a prospective multicentric study. Methods Data from patients in 15 clinical centers who had started a DAA regimen and were receiving comedications during March 2015 to March 2016 were prospectively evaluated. The DDIs for each regimen and comedication were assigned according to HepC Drug Interactions (www.hep-druginteractions.org). Results Of the 449 patients evaluated, 86 had mild liver disease and 363 had moderate-to-severe disease. The use of a single comedication was more frequent among patients with mild liver disease (p = 0.03), whereas utilization of more than three drugs among those with moderate-to-severe disease (p = 0.05). Of the 142 comedications used in 86 patients with mild disease, 27 (20%) may require dose adjustment/closer monitoring, none was contraindicated. Of the 322 comedications used in 363 patients with moderate-to-severe liver disease, 82 (25%) were classified with potential DDIs that required only monitoring and dose adjustments; 10 (3%) were contraindicated in severe liver disease. In patients with mild liver disease 30% (26/86) used at least one drug with a potential DDI whereas of the 363 patients with moderate-to-severe liver disease, 161 (44%) were at risk for one or more DDI. Conclusions Based on these results, we can estimate that 30–44% of patients undergoing DAA and taking comedications are at risk of a clinically significant DDI. This data indicates the need for increased awareness of potential DDI during DAA therapy, especially in patients with moderate-to-severe liver disease. For several drugs, the recommendation related to the DDI changes from “dose adjustment/closer monitoring”, in mild to moderate liver disease, to “the use is contraindicated” in severe liver disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|